Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Serving Size: 1ml (approx
J.BrownB
actinium-225 alpha emitter / OncologyPancreatic cancerPhase 1planned 3assets Budoprutug IVCD19 / monoclonal antibody / immune-mediated diseasesPrimary Membranous NephropathyPhase 2Immune ThrombocytopeniaPhase 1Systemic Lupus ErythematosusPhase 1 Budoprutug SCCD19 / monoclonal antibody / immune-mediated diseasesAutoimmune DiseasePhase 1healthy volunteer trial CLYM116CLYM116 / APRIL / monoclonal antibody / immune-mediated diseasesIgA NephropathyPhase 1healthy volunteer trial 3assets cleminorextonORX750 / OX2R / oral orexin receptor 2 agonist / Sleep-wake disordersNarcolepsy Type 1 (NT1)Phase 2aactiveNarcolepsy Type 2 (NT2)Phase 2aactiveIdiopathic Hypersomnia (IH)Phase 2aactive ORX142ORX142 / OX2R / oral orexin receptor 2 agonist / Neurology/neurodegenerative disordersNeurological & neurodegenerative disordersPhase 1active ORX489ORX489 / OX2R / oral orexin receptor 2 agonist / NeuropsychiatryNeuropsychiatric disordersPreclinicalactive 3assets CTIM-76CTIM-76 / CLDN6 x CD3 / TCE bispecific antibody / Oncologyrecurrent ovarian cancer and other advanced solid tumorsPhase 1ongoingplatinum-resistant ovarian cancerPhase 1FDA Fast TrackUS CT-95CT-95 / MSLN x CD3 / TCE bispecific antibody / Oncologyadvanced solid tumorsPhase 1ongoing CT-202CT-202 / Nectin-4 x CD3 / TCE bispecific antibody / OncologyNectin-4-positive solid tumorsPhase 1planned
Most specialty pharmacies have protocols for replacing temperature-compromised medications, though policies vary by pharmacy, insurer, and manufacturer
